Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H25NO3.ClH |
| Molecular Weight | 315.836 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC(=CC=C1)[C@]2(O)C[C@@H](O)CC[C@H]2CN(C)C
InChI
InChIKey=BCTAUJYAQUAGMU-ZPQOTBKHSA-N
InChI=1S/C16H25NO3.ClH/c1-17(2)11-13-7-8-14(18)10-16(13,19)12-5-4-6-15(9-12)20-3;/h4-6,9,13-14,18-19H,7-8,10-11H2,1-3H3;1H/t13-,14-,16+;/m0./s1
Axomadol is a centrally active analgesic agent with opioid agonistic properties and with inhibitory effects on the reuptake of the monoamines noradrenaline and, to serotonin [5‐hydroxytrypyamine (5‐HT)]. The drug participated in phase II clinical trials in the treatment of patients with moderate to severe chronic low back pain. As a result, the axomadol didn’t meet predetermined study endpoint, and studies were discontinued.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Axomadol
Created by
admin on Tue Apr 01 19:42:28 GMT 2025 , Edited by admin on Tue Apr 01 19:42:28 GMT 2025
|
PRIMARY | |||
|
187219-95-0
Created by
admin on Tue Apr 01 19:42:28 GMT 2025 , Edited by admin on Tue Apr 01 19:42:28 GMT 2025
|
PRIMARY | |||
|
B77S5W28H9
Created by
admin on Tue Apr 01 19:42:28 GMT 2025 , Edited by admin on Tue Apr 01 19:42:28 GMT 2025
|
PRIMARY | |||
|
70220033
Created by
admin on Tue Apr 01 19:42:28 GMT 2025 , Edited by admin on Tue Apr 01 19:42:28 GMT 2025
|
PRIMARY | |||
|
DTXSID901351059
Created by
admin on Tue Apr 01 19:42:28 GMT 2025 , Edited by admin on Tue Apr 01 19:42:28 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
